葡萄膜炎性黄斑水肿七年结局:MUST试验及随访研究结果
该研究对多中心葡萄膜炎类固醇治疗(MUST)试验及随访研究中177例葡萄膜炎性黄斑水肿(ME)患者的248只眼进行纵向随访,采用OCT每年评估。结果显示7年内ME累积消退率达94%,但7年内复发累积率为43%;ME消退眼视力平均提高6.24个字母,而未消退眼无视力增益,当年新发或复发ME眼平均视力下降8.65个字母。
要点
- 葡萄膜炎性ME在7年内累积消退率高达94%,但复发常见(7年累积43%)。
- OCT显示视网膜前膜与ME消退可能性降低相关(HR 0.74,95%CI 0.55-1.01,P=0.05)。
- ME消退眼视力平均提高6.24个字母,提示控制炎症和消退ME可能是视力相关治疗目标。
核心结论
- 给予足够时间和治疗,几乎所有葡萄膜炎性ME均可消退,但复发常见。
- ME消退眼视力结果更好,提示控制炎症和消退ME可能是视力相关治疗目标。
研究设计与样本
- 多中心葡萄膜炎类固醇治疗(MUST)试验及随访研究的纵向队列随访。
- 纳入177例葡萄膜炎性ME患者的248只眼,基线及每年进行OCT测量,由对临床数据设盲的读片中心分级员分级。
主要发现
- 在随访≥1年的227只ME眼中,7年内任意时间点ME累积消退率为94%(95%CI 89-97)。
- OCT上视网膜前膜与ME消退可能性降低相关(HR 0.74,95%CI 0.55-1.01,P=0.05)。
- 在177只ME已消退眼中,7年内复发累积率为43%(95%CI 32-51)。
- ME消退眼在1年随访间期相比无ME眼平均提高6.24个字母(95%CI 4.40-8.09,P<0.001)。
- ME未消退眼无视力增益(平均变化-1.30个字母,95%CI -2.70至0.09,P=0.065),当年新发或复发ME眼平均下降8.65个字母(95%CI -11.5至-5.84,P<0.001)。
关键数值与推荐
- 黄斑水肿定义为时域OCT上中心黄斑厚度(CMT)≥240 μm或时域OCT等效值。
- ME消退定义为OCT上黄斑厚度正常化。
- ME复发定义为先前已消退眼黄斑厚度增加至≥240 μm。
临床怎么用
- 对葡萄膜炎性ME患者应长期随访,因消退后复发常见。
- 控制炎症和促进ME消退可能有助于视力获益。
- OCT发现视网膜前膜可能提示ME消退可能性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the long-term outcomes of uveitic macular edema (ME). DESIGN: Longitudinal follow-up of a cohort of participants in a randomized clinical trial. PARTICIPANTS: A total of 248 eyes of 177 participants with uveitic ME enrolled in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. METHODS: OCT measurements, taken at baseline and annually, were graded by reading center graders masked to clinical data. Macular edema was defined as a center macular thickness (CMT) ≥240 μm on time-domain OCT or time-domain OCT equivalent. Resolution of ME was defined as normalization of macular thickness on OCT. Relapse of ME was defined as increase in macular thickness to ≥240 μm in an eye that previously had resolution. Visual acuity was measured at each visit with logarithmic visual acuity charts. MAIN OUTCOME MEASURES: Resolution and relapse of ME. Visual acuity. RESULTS: Among 227 eyes with ME followed ≥1 year, the cumulative percent of eyes with ME resolving at any point during 7 years was 94% (95% confidence interval [CI], 89-97). Epiretinal membranes on OCT were associated with a lower likelihood of ME resolution (hazard ratio [HR], 0.74; 95% CI, 0.55-1.01; P = 0.05). Among 177 eyes with resolved ME, the cumulative percent with relapse within 7 years was 43% (95% CI, 32-51). Eyes in which ME resolved gained a mean of 6.24 letters (95% CI, 4.40-8.09; P < 0.001) compared with eyes that remained free from ME during the 1-year follow-up intervals, whereas eyes in which ME did not resolve experienced no gain in vision (mean change -1.30 letters; 95% CI, -2.70 to 0.09; P = 0.065), and eyes that developed ME during the year (incident or relapsed) experienced a mean loss of -8.65 letters (95% CI, -11.5 to -5.84, P < 0.001). CONCLUSIONS: Given sufficient time and treatment, nearly all uveitic ME resolves, but episodes of relapse were common. Visual acuity results were better among eyes with resolved ME, suggesting that control of inflammation and resolution of ME might be visually relevant treatment targets.
引用
- Tomkins-Netzer O, Lightman SL, Burke AE, et al. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2020. PMID: 32918964. doi:10.1016/j.ophtha.2020.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。